Brought to you by 
Novartis gets majority stake in Idenix for CHF352; deal later restructured
02 Aug 2012
Executive Summary
Novartis Pharma AG paid CHF352.7mm ($255mm) in cash to shareholders of Idenix Pharmaceuticals (antiviral therapeutics) for a 51% stake in the company.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Includes Contract
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gets majority stake in Idenix for CHF352; deal later restructured
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice